Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Lasers Med Sci ; 38(1): 177, 2023 Aug 07.
Artículo en Inglés | MEDLINE | ID: mdl-37544939

RESUMEN

The main objective of this in vivo study was to investigate the effect of different low-level laser therapy (LLLT) doses on polycystic ovary syndrome (PCOS). In the present experimental study, a single dosage of estradiol valerate (EV) was administered to induce PCOS in female rats. After administration of the EV for induction of PCOS, rats were divided into 5 groups (n = 8/group): C group (animals that were not exposed to any form of procedure), PC group (no treatment following EV induction), L1 group (1 J/cm2 LLLT treatment following EV induction), L2 group (2 J/cm2 LLLT treatment following EV induction), L3 group (6 J/cm2 LLLT treatment following EV induction). The results indicated that no significant difference was found in the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and progesterone (P4) between the C and L2 groups (p < 0.05). Although the serum levels of testosterone (T) were significantly higher in the C group compared with other groups (p < 0.05), the L2 group was determined to be the closest to the C group. Additionally, the LH, FSH, and T receptor level of the L2 group was closest to the C group. In conclusion, a 2 J/cm2 dosage of LLLT (L2 group) can be considered the most potentially effective treatment of PCOS in the rat. However, more studies are needed to determine the optimal dose of LLLT for the treatment of PCOS.


Asunto(s)
Terapia por Luz de Baja Intensidad , Síndrome del Ovario Poliquístico , Animales , Femenino , Ratas , Estradiol/toxicidad , Hormona Folículo Estimulante , Hormona Luteinizante , Síndrome del Ovario Poliquístico/radioterapia , Testosterona
2.
Neurochem Res ; 46(2): 379-395, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33201400

RESUMEN

Paclitaxel (PTX) is an antineoplastic agent commonly used in the treatment of solid tumors and is known to cause dose-limiting peripheral neurotoxicity. This study was performed to evaluate the protective effect of curcumin (CUR) against PTX-induced spinal cord and sciatic nerve injuries in rats. The rats were administered PTX (2 mg/kg, BW) intraperitoneally for the first 5 consecutive days followed by administration of CUR (100 and 200 mg/kg, BW daily in corn oil) orally for 10 days. Our results showed that CUR significantly reduced mRNA expression levels of NF-κB, TNF-α, IL-6, iNOS and GFAP whereas caused an increase in levels of Nrf2, HO-1 and NQO1 in the spinal cord and sciatic nerve of PTX-induced rats. In addition, CUR suppressed the activation of apoptotic and autophagic pathways by increasing Bcl-2 and Bcl-xL, and decreasing p53, caspase-3, Apaf-1, LC3A, LC3B and beclin-1 mRNA expression levels. The results showed that CUR also maintained the spinal cord and sciatic nerve histological architecture and integrity by both LFB staining and H&E staining. Immunohistochemical expressions of 8-OHdG, caspase-3 and LC3B in the PTX-induced spinal cord tissue were decreased after administration of CUR. Taken together, our findings demonstrated that CUR has protective effects on PTX-induced spinal cord and sciatic nerve injuries in rats.


Asunto(s)
Curcumina/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Nervio Ciático/efectos de los fármacos , Neuropatía Ciática/tratamiento farmacológico , Traumatismos de la Médula Espinal/tratamiento farmacológico , Animales , Apoptosis/efectos de los fármacos , Autofagia/efectos de los fármacos , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Masculino , Paclitaxel , Ratas Sprague-Dawley , Nervio Ciático/patología , Neuropatía Ciática/inducido químicamente , Neuropatía Ciática/patología , Médula Espinal/efectos de los fármacos , Médula Espinal/patología , Traumatismos de la Médula Espinal/inducido químicamente , Traumatismos de la Médula Espinal/patología
3.
Fish Physiol Biochem ; 44(5): 1409-1420, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29959587

RESUMEN

We aimed to investigate the modulating effects of dietary borax on the pathways in rainbow trout brain exposed to copper. For this aim, a comprehensive assessment was performed including biochemical (acetylcholinesterase (AChE), malondialdehyde (MDA), oxidative DNA damage (8-hydroxy-2'-deoxyguanosine (8-OHdG), and caspase-3 levels) and transcriptional parameters (heat shock protein 70 (HSP70) and cytochromes P450 (CYP1A), glutathione peroxidase (gpx), superoxide dismutase (sod), and catalase (cat)) parameters and immunohistochemically staining of 8-OHdG. Special fish feed diets were prepared for the trial. These diets contained different concentrations of borax (1.25, 2.5, and 5 mg/kg) and/or copper (500 and 1000 mg/kg) at the period of pre- and co-treatment strategies for 21 days. At the end of the treatment periods, brain tissue was sampled for each experimental group. As a result, the biochemical parameters were increased and AChE activity decreased in the copper and copper-combined groups in comparison with the control group and also with only borax applications (p < 0.05). We observed an increase or decrease in particular biochemical parameters for the borax group in every application and we established that borax had protective effect against copper toxicity by decreasing and/or increasing the relevant biochemical parameters in brain tissue of fish. The biochemical results of borax and its combinations corresponded to the observations of gene expression data, which similarly concluded that HSP70 and CYP1A genes were strongly induced by copper (p < 0.05). In addition, the expression levels of the sod, cat, and gpx genes in the fish brains exposed to borax and the borax combination groups were significantly higher than the only copper-treated groups. In conclusion, borax supplementation provided significant protection against copper-induced neurotoxicity in trout.


Asunto(s)
Boratos/farmacología , Cobre/toxicidad , Enfermedades de los Peces/inducido químicamente , Fármacos Neuroprotectores/farmacología , Oncorhynchus mykiss , 8-Hidroxi-2'-Desoxicoguanosina , Animales , Boratos/administración & dosificación , Caspasa 3/genética , Caspasa 3/metabolismo , Cobre/administración & dosificación , Desoxiguanosina/análogos & derivados , Desoxiguanosina/sangre , Relación Dosis-Respuesta a Droga , Enfermedades de los Peces/sangre , Enfermedades de los Peces/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Fármacos Neuroprotectores/administración & dosificación
4.
Arch Physiol Biochem ; 124(5): 448-457, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29302997

RESUMEN

Doxorubicin (DXR) is one of the most important chemotherapeutic agent. However, nephrotoxicity reduces its clinical utility in humans. The aim of the study was to investigate protective effects of curcumin (CMN) against DXR-induced nephrotoxicity. Rats were subjected to oral treatment of CMN (100 and 200 mg/kg body weight) for 7 days. Nephrotoxicity was induced by single intra peritoneal injection of DXR (40 mg/kg body weight) on the fifth day and then the experiment was terminated on the eighth day. Nephroprotective effects of CMN were associated with decrease in serum toxicity markers and increase in antioxidant enzyme activities. CMN was able to reduced the levels of inflammatory markers such as TNF-α, NF-κB, IL-1ß, iNOS and COX-2 in the rats. It also reduced the expressions of apoptotic marker including caspase-3, and oxidative DNA damage marker including 8-OHdG. Collectively, these findings indicated that CMN protect against DXR-induced nephrotoxicity.


Asunto(s)
Apoptosis/efectos de los fármacos , Curcumina/uso terapéutico , Doxorrubicina/antagonistas & inhibidores , Riñón/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Sustancias Protectoras/uso terapéutico , Insuficiencia Renal/prevención & control , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/uso terapéutico , Antibióticos Antineoplásicos/efectos adversos , Antibióticos Antineoplásicos/química , Antioxidantes/administración & dosificación , Antioxidantes/efectos adversos , Antioxidantes/uso terapéutico , Biomarcadores/sangre , Biomarcadores/metabolismo , Curcumina/administración & dosificación , Curcumina/efectos adversos , Ciclooxigenasa 2/química , Ciclooxigenasa 2/metabolismo , Daño del ADN/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Doxorrubicina/efectos adversos , Riñón/inmunología , Riñón/metabolismo , Riñón/patología , Peroxidación de Lípido/efectos de los fármacos , Masculino , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo II/metabolismo , Oxidación-Reducción , Sustancias Protectoras/administración & dosificación , Sustancias Protectoras/efectos adversos , Distribución Aleatoria , Ratas Wistar , Insuficiencia Renal/inducido químicamente , Insuficiencia Renal/inmunología , Insuficiencia Renal/metabolismo , Inhibidores de Topoisomerasa II/efectos adversos , Inhibidores de Topoisomerasa II/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA